Management of Peripheral Neuropathy
First-Line Pharmacological Management
- The American Society of Clinical Oncology recommends duloxetine as the first-line treatment for painful peripheral neuropathy, particularly for chemotherapy-induced peripheral neuropathy, with the strongest evidence supporting its efficacy 1, 2, 3
- Duloxetine has demonstrated efficacy in reducing both painful and non-painful symptoms, and should be tapered slowly when discontinuing to avoid withdrawal symptoms 1
- Gabapentin is an alternative to pregabalin for neuropathic pain, though evidence for chemotherapy-induced peripheral neuropathy is less robust 4
- Tricyclic antidepressants, such as nortriptyline and desipramine, are effective for several types of neuropathic pain, but should be used with caution in patients with cardiac disease 4
Management of Specific Types of Peripheral Neuropathy
- Early detection and dose adjustment of neurotoxic chemotherapy agents, such as bortezomib and thalidomide, can help reduce side effects while maintaining anti-tumor efficacy 5, 6
- For established chemotherapy-induced peripheral neuropathy, duloxetine is the only treatment with strong evidence of benefit 1, 2
- Acetyl-L-carnitine is not recommended for chemotherapy-induced peripheral neuropathy based on negative trial results 1
- For bortezomib-induced neuropathy, early detection and dose adjustment algorithms are crucial 5, 6
- For IgM-related neuropathy, consider plasmapheresis for aggressive or progressing neuropathy, followed by consolidation with chemotherapy 7
- Single-agent rituximab can be considered for mild, slowly progressive neuropathy 7
Monitoring and Follow-up
- Periodically reassess pain and health-related quality of life 4
- If partial pain relief is achieved with one agent, consider adding another first-line medication 4
- If inadequate pain relief occurs after an adequate trial, switch to an alternative first-line medication 4